[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cardurion Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100650537","phase-2-a-trial-of-crd-4730-in-hfref-100650537",false,"NCT07750873","A Trial of CRD-4730 in HFrEF","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of CRD-4730 in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)","CALIBRATE-HF","Inclusion Criteria:\n\n* Adult male or female patient ≥ 18 years of age and ≤ 85 years of age at the time of screening.\n* Has a medical history supporting a diagnosis of clinical chronic heart failure (HF) syndrome with a duration of at least 8 weeks prior to the time of screening and current NYHA functional class II to III (based on investigator's assessment).\n* Has left ventricular ejection fraction ≤ 40% by a centrally read transthoracic echocardiogram performed during screening.\n* Has NT-proBNP level ≥ 600 pg\u002FmL (70.8 pmol\u002FL) at the time of screening. Patients in atrial fibrillation or flutter at the time of screening are required to have an NT-proBNP level of ≥ 900 pg\u002FmL (106.4 pmol\u002FL).\n* Is receiving optimized and stable guideline directed HF therapy (per applicable regional or national guidelines).\n\nExclusion Criteria:\n\n* Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 4 weeks of the time of screening or during the Screening Period.\n* Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration.\n* Has acute coronary syndrome, unstable angina, persistent angina at rest, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, cardiac valve repair (surgical or nonsurgical) or surgical replacement, or carotid angioplasty within 8 weeks prior to screening or during the Screening Period.\n* Has clinical suspicion of infiltrative cardiomyopathy (eg, amyloid, sarcoid), hypertrophic cardiomyopathy (obstructive or non-obstructive), or HF secondary to severe valvular disease, active myocarditis, active pericarditis, or clinically significant congenital heart disease.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years","85 Years",{"count":21,"type":22},525,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","CRD-4730 is a calcium\u002Fcalmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (HFrEF). Participants will be randomized to 1 of 4 study groups and receive investigational study drug or placebo twice daily (BID) for 24 weeks of treatment.",[28],"Heart Failure With Reduced Ejection Fraction (HFrEF)",[30],"Heart failure","RECRUITING","2026-08-05",{"date":34,"type":35},"2026-08-06","ACTUAL",{"date":37,"type":35},"2026-07-15",{"date":39,"type":22},"2028-09",{"name":41,"class":42},"Cardurion Pharmaceuticals, Inc.","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":53},"100566724","phase-2-a-phase-2-study-of-crd-4730-in-cpvt-100566724","NCT06658899","A Phase 2 Study of CRD-4730 in CPVT","A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia","CPVT","Inclusion Criteria:\n\nEach participant must meet all the following criteria to be enrolled in this study:\n\n1. The participant is male or female, ≥18 years of age and of legal adult age in accordance with local requirements.\n2. The participant has a confirmed CPVT diagnosis, based on genetic screening for a pathogenic ryanodine receptor (RYR2) mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the Investigator and documented in the study source records.\n3. The participant can perform an EST during which frequent premature ventricular contractions (PVCs; ≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the Investigator.\n4. The participant has been on a stable dose of at least 1 antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks prior to Screening, unless the participant has been unable to tolerate antiarrhythmic therapy previously.\n5. Adheres to all contraceptive criteria.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded from the study:\n\n1. The participant has clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.\n2. The participant has a clinically significant abnormal ECG not explained by the diagnosis of CPVT at Screening or clinically significant abnormal intervals, such as prolonged QT.\n3. The participant has a history of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of Screening.\n4. The participant undergoes implantable cardioverter-defibrillator (ICD) implantation or has sympathetic nerve denervation within 3 months of Screening.\n5. The participant has an anticipated change in exercise regimen or new exercise program during the course of the study.\n6. The participant has a history of malignancy within the past 5 years at Screening, with the exception of successfully treated basal cell carcinoma or nonmetastatic squamous cell carcinoma of the skin or cervical carcinoma in situ. Prior exposure to chest radiation for any malignancy is exclusionary.\n7. The participant has abnormal blood pressure, defined as supine symptomatic hypotension, systolic blood pressure \\>150 mm Hg or diastolic blood pressure \\>90 mm Hg, or symptomatic bradycardia or a heart rate \\>100 bpm at Screening and\u002For on Day 1. Blood pressure and pulse should be measured after the participant has been in the seated position after 5 minutes of rest.\n8. The participant has hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × (upper limit of normal \\[ULN\\]) and\u002For total bilirubin \\>1.5 × ULN at Screening (unless secondary to confirmed Gilbert syndrome).\n9. The participant has acute or chronic hepatitis B (HBV; defined as hepatitis B surface antigen \\[HBsAg\\] reactive), acute or chronic hepatitis C virus (HCV; defined as detection of HCV antibody and RNA \\[qualitative\\]), or human immunodeficiency virus (HIV) infection.\n10. The female participant is pregnant, lactating\u002Fbreastfeeding, or has plans to become pregnant during the study or within 3 months following the last study drug administration.\n11. The participant has taken any antiarrhythmic drug in addition to their stable, chronic regimen unless it has been at least 5 half-lives since administration at the time of Screening.","99 Years",{"count":53,"type":22},12,[25],"This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.",[57],"Catecholaminergic Polymorphic Ventricular Tachycardia",[59,49,60,61,62,63,57,64,65],"CaMKII","Ventricular Tachycardia","CRD-4730","Cardiovascular","Arrhythmia","CaM kinase II","Calmodulin-dependent protein kinase II","2026-07-08",{"date":68,"type":35},"2026-07-09",{"date":70,"type":35},"2025-12-01",{"date":72,"type":22},"2027-04",{"name":41,"class":42},""]